Invivyd posts third quarter 2026 financial results with recent business updates

Invivyd posts third quarter 2026 financial results with recent business updates
Invivyd Q3 2026 results out

Invivyd has released its financial results for the third quarter 2026, alongside an update on recent business activities.

The company made the announcement through an official update, but further details on performance metrics or development specifics were not disclosed in the tweet.

Earlier this year, Invivyd introduced VMS063, a new monoclonal antibody candidate for measles treatment and prevention at IDWeek 2026. The company has been focused on developing therapies addressing infectious diseases. Previous updates provided details on product pipelines, but recent disclosures remain limited.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.